Megha Das 
With a 32% drop in value during the month of August, Brightcom Group shares are the poorest performing company in the NSE 500.
BOB Economics Research reports that the monthly percentage decline for Tanla Platforms is 18.5%, for Vedanta it is 15.8%, and for Medplus Health Services it is 15.4%.
TCNS Clothing has dropped 13.3%, Cummins India has dropped 13.2%, Radico Khaitan has dropped 13%, Redington has dropped 13%, Borosil Renewables has dropped 12.8%, Hindustan Petroleum has dropped 12%, Bombay Burmah has dropped 11.8%, Macrotech Developers has dropped 11.7%, TCI Express is down 11.6%, and Apollo Tyres has dropped 10.3%.
Stocks in RattanIndia Enterprises (up 52%), Kalyan Jewellers (up 41%), Swan Energy (up 38%), Indiabulls Housing Finance (up 38%), Cochin Shipyard (up 35%), Gland Pharma (up 33%), Apar Industries (up 32%), Indian Railway Finance Corporation (up 31%), BSE (up 31%), Suzlon Energy (up 29.6%), Archean Chemical (up 28.8%), and Suzlon Energy (up 31
Other notable risers include Jindal Worldwide (26.6%), Linde India (26%), Supreme Industries (25.6%), Cera Sanitaryware (25.6%), Escorts Kubota (24.4%), Jubilant Ingrevia (24%), Jubilant Pharmova (24%), KSB (23%), Tamilnad Mercantile Bank (22.8%), BEML (22.4%), JSW Energy (21.6%), and Dixon Technologies (21.4%).
According to the survey, Nifty50 performed similarly to other international indexes in August, but it has lagged behind the rest of the year. In August, most major global indexes fell, with Chinese indices among the poorest performers. Both the Hang Seng and the Shenzhen Composite fell by 8%. The S&P 500 fell 1.6% and the Nifty50 fell 2.5%. After accounting for the recent drop, Nifty50’s forward PE multiple of 1 is now in line with its 5y average, indicating a reasonably priced market. While the broader market has gained double digits so far this year, the Nfty50 has only gained 6.3%.
Small and mid-cap stocks kept their momentum, while most industry benchmarks were down. In August, the Nifty mid and small cap indexes gained 4%. A 3% uptick in the Nifty IT index suggests the industry may have hit bottom. Since reduced generic drug price pressure in the United States was anticipated, the pharmaceutical industry also saw some improvement. However, the improvement in the two industries was also aided by the decline in INR. However, the majority of other significant industries saw a decrease in monthly return. The analysis found that mid and small cap funds continue to get more money than their fair share, which has led to a self-sustaining cycle of outperformance and subsequent inflow.
